

WA'S NOBEL LAUREATE, DR. BARRY MARSHALL REVERSES THE BRAIN DRAIN AND ATTRACTS TOP INTERNATIONAL SCIENTISTS TO PERTH

Since raising capital in 2007, Ondek Pty Ltd (Dr Barry Marshall's biotechnology venture) has invested in a global recruitment process to attract the best scientists available in the world to help him develop an oral vaccine for influenza and cholera.

Ondek now has a team of fifteen scientists from around the world with expertise in microbiology, immunology, genetic engineering, H.pylori, vaccine development using genetically modified live attenuated bacteria and successfully navigating through human trials.

Ondek's Executive Chairman, Peter Hammond, said "the likelihood of achieving global success for companies like Ondek is completely dependent on the quality of the scientific team. The ability of Dr. Marshall to attract such a high calibre group of scientists based here in Sir Charles Gardiner Hospital is an incredible opportunity for Western Australia. With the team that has been assembled, many of whom have relocated their entire families to Perth, Ondek has the potential to become a global player in the biotech industry from its base here in Perth."

Ondek's scientific team is lead by Dr. Marshall and managed by Dr. Mohammed Benghezal, a biochemist and a molecular biologist attracted from Switzerland with extensive experience in managing very successful biotechnology research teams.



He is supported by Dr Fulurija, an Australian graduate from Perth that has been attracted back from Switzerland after a successful career in the field of novel vaccines and immunology, Dr. Yakhya Dieye, a microbiologist from Senegal with extensive

US expertise in developing vaccines using the Salmonella bacteria as the delivery vehicle, and Dr. Hans-Olof Nilsson, a microbiologist attracted from Sweden with extensive experience in H.pylori research.



Ondek's mission is to be a leading research and development company for drug delivery systems utilising its core technology, the Helicobacter Pylori Platform Technology ("HPPT"). The HPPT utilizes a genetically modified H.pylori bacterium that carries new genes for specific purposes. The HPPT will be administered orally, for example contained in a Yakult type drink or yoghurt. By expressing these new genes the HPPT should create an immune response in humans providing a vaccination against one or more diseases. The HPPT could potentially be used to deliver multiple vaccines with one dose or alternatively simple drugs, biologics and other therapeutics

Having proved the core technology in animals for their two lead products, an oral seasonal influenza and cholera vaccine, Ondek will be raising capital to fund the completion of Phase IIA human trials for these products.

Ondek's commercial development and capital raisings are managed by Exto Partners Pty Ltd. Exto Partners is a venture capital and private equity investor that works with a network of angel investors to invest in, manage and grow Australian businesses (www.extopartners.com).

For more details on Ondek, please contact Peter Hammond at phammond@ondek.com or visit the Ondek website at www.ondek.com.